AU2013265025B2 - Anti -transglutaminase 2 antibodies - Google Patents

Anti -transglutaminase 2 antibodies Download PDF

Info

Publication number
AU2013265025B2
AU2013265025B2 AU2013265025A AU2013265025A AU2013265025B2 AU 2013265025 B2 AU2013265025 B2 AU 2013265025B2 AU 2013265025 A AU2013265025 A AU 2013265025A AU 2013265025 A AU2013265025 A AU 2013265025A AU 2013265025 B2 AU2013265025 B2 AU 2013265025B2
Authority
AU
Australia
Prior art keywords
antibody
pct
antigen
rule
substitute sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013265025A
Other languages
English (en)
Other versions
AU2013265025A1 (en
Inventor
Alex Brown
Tim Johnson
David Matthews
Phil WATSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
Medical Research Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46546551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013265025(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical Research Council Technology filed Critical Medical Research Council Technology
Publication of AU2013265025A1 publication Critical patent/AU2013265025A1/en
Application granted granted Critical
Publication of AU2013265025B2 publication Critical patent/AU2013265025B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AU2013265025A 2012-05-24 2013-05-24 Anti -transglutaminase 2 antibodies Active AU2013265025B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1209096.5A GB201209096D0 (en) 2012-05-24 2012-05-24 Compounds
GB1209096.5 2012-05-24
PCT/GB2013/051373 WO2013175229A1 (en) 2012-05-24 2013-05-24 Anti -transglutaminase 2 antibodies

Publications (2)

Publication Number Publication Date
AU2013265025A1 AU2013265025A1 (en) 2014-12-04
AU2013265025B2 true AU2013265025B2 (en) 2018-04-26

Family

ID=46546551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013265025A Active AU2013265025B2 (en) 2012-05-24 2013-05-24 Anti -transglutaminase 2 antibodies

Country Status (39)

Country Link
US (3) US10005846B2 (enExample)
EP (2) EP2855530B1 (enExample)
JP (2) JP6411998B2 (enExample)
KR (1) KR102091223B1 (enExample)
CN (1) CN104321346B (enExample)
AU (1) AU2013265025B2 (enExample)
BR (1) BR112014029089B1 (enExample)
CA (1) CA2874488C (enExample)
CL (1) CL2014003125A1 (enExample)
CO (1) CO7151528A2 (enExample)
CY (2) CY1121932T1 (enExample)
DK (2) DK2855530T3 (enExample)
EA (1) EA036810B1 (enExample)
EC (1) ECSP14030942A (enExample)
ES (2) ES2835383T3 (enExample)
GB (1) GB201209096D0 (enExample)
HR (2) HRP20191293T1 (enExample)
HU (2) HUE052490T2 (enExample)
IL (1) IL235369B (enExample)
IN (1) IN2014MN02231A (enExample)
LT (2) LT2855530T (enExample)
MA (1) MA37670B1 (enExample)
ME (1) ME03393B (enExample)
MX (1) MX367517B (enExample)
MY (1) MY185966A (enExample)
NZ (1) NZ701424A (enExample)
PE (1) PE20150346A1 (enExample)
PH (1) PH12014502582A1 (enExample)
PL (2) PL3521315T3 (enExample)
PT (2) PT3521315T (enExample)
RS (2) RS59135B1 (enExample)
SG (1) SG11201407053YA (enExample)
SI (2) SI2855530T1 (enExample)
SM (2) SMT202100014T1 (enExample)
TN (1) TN2014000458A1 (enExample)
TR (1) TR201906781T4 (enExample)
UA (1) UA117657C2 (enExample)
WO (1) WO2013175229A1 (enExample)
ZA (1) ZA201408213B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110055235A (zh) * 2019-05-14 2019-07-26 深圳市亚辉龙生物科技股份有限公司 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法
FR3117599B1 (fr) * 2020-12-16 2024-11-29 Oreal Méthode de pronostic et/ou de diagnostic d’un état pelliculaire du cuir chevelu
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
CA3238305A1 (en) 2021-11-18 2023-05-25 Timothy Scott JOHNSON Method for the treatment of progressive chronic interstitial lung disease
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease
GB202118010D0 (en) 2021-12-13 2022-01-26 UCB Biopharma SRL Method for detecting and/or quantifying crosslinks formed by transglutaminases
CN116515786B (zh) * 2023-04-26 2024-05-28 广东医科大学 一种人tgm3乙酰化多肽、抗原、抗体及其制备方法和应用
WO2025153465A1 (en) * 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd
WO2026162317A1 (en) 2025-01-28 2026-08-06 Chiesi Farmaceutici S.P.A. Treatment of progressive chronic interstitial lung disease with an anti-tg2 antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) * 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
WO2010113025A2 (en) * 2009-04-01 2010-10-07 University Of Debrecen Diagnosis of gluten-induced autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912120A (en) 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
AU1268192A (en) 1991-01-04 1992-08-17 Board Of Regents, The University Of Texas System Cloning and expression of tissue transglutaminases
WO1998004245A1 (en) 1996-07-25 1998-02-05 The Victoria University Of Manchester Use of transglutaminase modulators to promote wound healing
GB0103024D0 (en) * 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
US20060211624A1 (en) 2003-02-02 2006-09-21 Goverment of the US, as Represented by Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
US8299040B2 (en) 2006-10-18 2012-10-30 Board Of Regents, The University Of Texas System Methods for treating cancer targeting transglutaminase
KR101746861B1 (ko) * 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
NZ595731A (en) 2009-03-19 2013-09-27 Univ Queensland Targets for growth factor signalling and methods of therapy
HU0900195D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis and treatment of gluten-induced autoimmune diseases
WO2011151395A2 (en) 2010-06-02 2011-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) * 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
WO2010113025A2 (en) * 2009-04-01 2010-10-07 University Of Debrecen Diagnosis of gluten-induced autoimmune diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Dl NIRO, R. ET AL: "Characterizing monoclonal antibody epitopes by filtered gene fragment phage display", BIOCHEMICAL JOURNAL vol. 388, no. 3,15 June 2005 (2005-06-15), pages 889-894 *
Dl NIRO, R. ET AL: "Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models", BMC BIOTECHNOLOGY, vol. 7, no. 1, 1 August 2007 (2007-08-01 ), page 46 *
N.N.: "Anti-transglutaminase 2 antibody [CUB 7402] (ab2386)", Abeam -Data sheet, 2010, Retrieved from the Internet: URL:http://www.abcam.com/transg lutaminase-2-antibody-cub-7 402-ab2386. htm I [retrieved on 2013-08-27] *
THE FASEB JOURNAL, vol. 21, no. 14, 20 July 2007 (2007-07-20), pages 4131-4143,ISSN: 0892-6638, DOI: 10.1096/fj.06-7598com; & Thung-S. Lai ET AL: "Supplemental data:", FASEB Journal, 20 July 2007 (2007-07-20), pages 1-6, *

Also Published As

Publication number Publication date
ZA201408213B (en) 2020-02-26
AU2013265025A1 (en) 2014-12-04
SMT202100014T1 (it) 2021-03-15
HK1203974A1 (en) 2015-11-06
RS59135B1 (sr) 2019-09-30
JP2015519897A (ja) 2015-07-16
SI3521315T1 (sl) 2020-12-31
BR112014029089B1 (pt) 2023-04-25
US10005846B2 (en) 2018-06-26
HUE052490T2 (hu) 2021-04-28
SMT201900407T1 (it) 2019-09-09
SI2855530T1 (sl) 2019-08-30
JP6411998B2 (ja) 2018-10-24
MA37670A1 (fr) 2016-05-31
CY1121932T1 (el) 2020-10-14
CN104321346B (zh) 2018-12-07
PL3521315T3 (pl) 2021-08-23
UA117657C2 (uk) 2018-09-10
MX367517B (es) 2019-08-26
PT2855530T (pt) 2019-07-08
EA036810B1 (ru) 2020-12-23
PE20150346A1 (es) 2015-03-05
CN104321346A (zh) 2015-01-28
EP3521315B1 (en) 2020-10-14
EP2855530B1 (en) 2019-05-01
CL2014003125A1 (es) 2015-08-21
DK3521315T3 (da) 2020-11-09
CY1123926T1 (el) 2022-05-27
KR20150013340A (ko) 2015-02-04
ME03393B (me) 2020-01-20
ES2835383T3 (es) 2021-06-22
EP2855530A1 (en) 2015-04-08
BR112014029089A2 (pt) 2019-06-25
US11718686B2 (en) 2023-08-08
IL235369B (en) 2019-05-30
RS61286B1 (sr) 2021-02-26
IN2014MN02231A (enExample) 2015-07-24
KR102091223B1 (ko) 2020-03-20
PH12014502582B1 (en) 2015-01-21
CA2874488C (en) 2021-09-07
ES2728856T3 (es) 2019-10-29
US10961319B2 (en) 2021-03-30
TN2014000458A1 (en) 2016-03-30
LT2855530T (lt) 2019-07-25
PL2855530T3 (pl) 2019-10-31
PH12014502582A1 (en) 2015-01-21
US20210101999A1 (en) 2021-04-08
MY185966A (en) 2021-06-14
PT3521315T (pt) 2020-10-29
US20150218289A1 (en) 2015-08-06
LT3521315T (lt) 2020-12-28
GB201209096D0 (en) 2012-07-04
MA37670B1 (fr) 2019-12-31
IL235369A0 (en) 2014-12-31
WO2013175229A1 (en) 2013-11-28
SG11201407053YA (en) 2014-12-30
NZ701424A (en) 2016-08-26
TR201906781T4 (tr) 2019-05-21
CO7151528A2 (es) 2014-12-29
US20180355060A1 (en) 2018-12-13
DK2855530T3 (da) 2019-06-24
HUE045539T2 (hu) 2019-12-30
JP2018166510A (ja) 2018-11-01
EA201492162A1 (ru) 2015-03-31
EP3521315A1 (en) 2019-08-07
ECSP14030942A (es) 2015-09-30
HRP20202059T1 (hr) 2021-02-19
CA2874488A1 (en) 2013-11-28
MX2014014264A (es) 2015-05-15
HRP20191293T1 (hr) 2019-10-18

Similar Documents

Publication Publication Date Title
US11718686B2 (en) Anti-transglutaminase 2 antibodies
JP7592022B2 (ja) 抗クローディン１８．２抗体及びその用途
CN108271376B (zh) 结合dll3和cd3的双特异性抗体构建体
US8999342B2 (en) Anti-fibroblast activation protein antibodies and methods and uses thereof
JP2004532608A (ja) ヒト化抗ＬＴ−β−Ｒ抗体
CA2759836A1 (en) Humanized axl antibodies
US20190194315A1 (en) Antibody drug conjugates
KR20230117183A (ko) 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도
EP3298044B1 (en) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
CN113683686A (zh) 抗新冠病毒中和性单克隆抗体的制备和应用
CN110964107B (zh) Met结合分子、其组合和用途
HK40012662A (en) Anti-transglutaminase 2 antibodies
HK40012662B (en) Anti-transglutaminase 2 antibodies
HK1203974B (en) Anti -transglutaminase 2 antibodies
JP2026501220A (ja) 抗ＴＧＦβ受容体１抗体及びその使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)